New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
11:38 EDTZMHZimmer recalls all 315 units of PEEK Ardis Inserter, FDA says
The FDA posted on its website that Zimmer issued a December 21 recall of its PEEK Ardis Inserter. Zimmer Spine has received reports of the PEEK Ardis Interbody Spacer breaking into fragments when too much lateral force is applied to the Ardis Inserter, the FDA said. If the PEEK Ardis Interbody Spacer breaks during implantation, surgical delays of up to 60 minutes could occur and health risks may include a tear in the thin covering of the spinal cord, cerebrospinal fluid leakage, significant blood loss and nerve injury, the agency added. On Dec. 20, Zimmer Spine modified their Medical Device Correction memo and initiated a voluntary recall of all 315 units of the PEEK Ardis Inserter.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
15:11 EDTZMHZimmer valuation not reflecting Biomet deal potential, says Cantor
Cantor says Zimmer remains its preferred name in orthopedics despite its "disappointing" Q2 report, as the firm believes the stock's valuation doesn't properly reflects the potential from its tie-up with Biomet. Cantor thinks Zimmer management's synergy targets are possibly conservative and raised its price target on the stock to $117 from $113.
08:27 EDTZMHZimmer 'confident' Biomet merger transaction to be completed in 1Q15
Subscribe for More Information
08:25 EDTZMHZimmer sees FY14 gross margin ratio at 73%-74%
Expects FY14 SG&A to be unchanged, although it says there will be a seasonally higher ratio in Q3. Sees FY14 tax rate of 25.5%.
08:25 EDTZMHZimmer sees Q3 EPS $1.29-$1.31, consensus $1.37
Subscribe for More Information
08:19 EDTZMHLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
07:48 EDTZMHZimmer cuts FY14 EPS to $6.00-$6.10 from $6.00-$6.20, consensus $6.12
Subscribe for More Information
07:47 EDTZMHZimmer reports Q2 adjusted EPS $1.49, consensus $1.49
Reports Q2 revenue $1.18b, consensus $1.21B
July 22, 2014
08:15 EDTZMHZimmer should be bought on any weakness from Q2 results, says RBC Capital
RBC Capital believes that consensus Q2 recon estimates for Zimmer may be "a bit optimistic," but the firm thinks that investors already partially anticipate a miss on that metric The firm recommends buying the stock on any weakness associated with Q2 results, as it thinks the company's valuation is favorable, given its growth outlook. RBC Capital keeps a $120 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use